Research Paper Volume 13, Issue 21 pp 24205—24218
YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma
- 1 Department of Nuclear Medicine (PET-CT Central), Xiangya Hospital, Central South University, Changsha, China
- 2 Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
- 3 Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- 4 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
- 5 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Received: July 19, 2021 Accepted: October 26, 2021 Published: November 8, 2021https://doi.org/10.18632/aging.203674
How to Cite
Copyright: © 2021 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hepatocellular carcinoma (HCC) is the most common high malignancy with insidious onset, invasive fast-growing, high recurrence rate and fatality. YTH domain family plays essential roles in development of HCC. However, the biological function of YTH domain family in HCC have not been clarified. Here, through evaluating the expression profiles of YTH domain family, we found that upregulated YTHDF1 might be more significant and valuable in development and progression of HCC. There was a strong correlation between YTHDC1, YTHDF1 and YTHDF2 and pathological stage of HCC patients. Kaplan-Meier plotter revealed that HCC patients with high level of YTHDF1 and YTHDF2 were highly related to a shorter overall survival time, and low level of YTHDF1 (p = 0.0017) has an important association with a longer progression-free survival time. Genetic alterations using cBioPortal revealed that the alteration rates of YTHDF3 were the highest. We also found that the functions of YTH domain family were linked to several cancer-associated pathways, including peptidyl-serine modification, peptidyl-tyrosine modification and negative regulation of cellular component movement. TIMER database indicated that the YTH domain family had a strong relationship with the infiltration of six types of immune cells (macrophages, neutrophils, CD8+ T-cells, B-cells, CD4+ T-cells and dendritic cells). Next, Ualcan databases revealed that the global methylation levels of YTHDC1 was higher in HCC patients, while YTHDF2 was lower in HCC patients. In conclusion, our findings will enhance the understanding of YTH domain family in HCC pathology, and provide novel insights into YTH-targeted therapy for HCC patients.